RecruitingPhase 3NCT07444476

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

Studying Autosomal dominant adult-onset proximal spinal muscular atrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Biogen
Principal Investigator
Medical Director
Biogen
Intervention
Salanersen(drug)
Enrollment
90 enrolled
Eligibility
15-60 years · All sexes
Timeline
20262032

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07444476 on ClinicalTrials.gov

Other trials for Autosomal dominant adult-onset proximal spinal muscular atrophy

Additional recruiting or active studies for the same condition.

See all trials for Autosomal dominant adult-onset proximal spinal muscular atrophy

← Back to all trials